Comparison of P-wave parameter changes after radiofrequency ablation and cryoballoon ablation for paroxysmal atrial fibrillation: An observational cohort study
posted on 2025-03-07, 10:20authored byIbrahim Antoun, Xin LiXin Li, Zakkariya Vali, Ahmed Abdelrazik, Riyaz Somani, Ghulam NgGhulam Ng
Background: Pulmonary vein isolation (PVI) for paroxysmal atrial fibrillation (PAF) can be performed using one-shot cryoballoon ablation (cryo) or point-by-point radiofrequency ablation (RF). This study compares the changes in P-wave parameters between both ablation methods. Methods: This single-centre retrospective study included contact force RF and second-generation cryo for PAF between 2018 and 2019. Procedure success was defined by freedom of ECG-documented AF at 12 months. Digital 12‑leads ECGs with 1–50 hertz bandpass filters were monitored directly during the procedure. Corrected P-wave duration (PWDc), P-wave voltage (PWV), P-wave dispersion (PWDisp), and P-wave terminal force in V1 (PTFV1) were measured and compared between RF and cryo. Additional ablations outside pulmonary veins were excluded. Results: The final analysis included 226 patients, and the freedom of AF rate was similar at the 12-month follow-up between RF and cryo (76 % vs 74 %, P = 0.12). PWDc and PWV increased and decreased, respectively in both arms. PTFV1 decreased in RF (−3.3 mm.s to −4.6 mm.s, P < 0.001) and cryo (−3.4 mm.s to −5.3 mm.s,P = 0.002). There were similar changes after RF and cryo in PWDc (F11, 1032 = 0.80, P = 0.85), PWV (F11, 1032 = 0.19,P = 0.06), and PWDisp (F11, 1032 = 0.16,P = 0.34) and PTFV1 (P = 0.39). Increased PWDc was correlated with failure of RF (hazard ratio [2.3], 95 % confidence interval [CI]: 1.4–5.9, p = 0.01) and cryo (HR: 2.1, 95 % CI (1.3–4.6), p = 0.02). Results were similar when patients on antiarrhythmic drugs were excluded. Conclusion: RF and cryo caused similar freedom of AF rate at 12 months in PAF and similar P-wave parameter changes.
Funding
Development of a successful novel technology for sudden cardiac death risk stratification for clinical use - LifeMap